Department of Medical Biology, Faculty of Medicine, Sakarya University, Sakarya, Turkey.
Department of Medical Biology, Faculty of Medicine, Bursa Uludag University, Bursa, Turkey.
J Biochem Mol Toxicol. 2019 Aug;33(8):e22338. doi: 10.1002/jbt.22338. Epub 2019 Apr 12.
The aim of this study was to investigate the combined effects of usnic acid (UA) and Tamoxifen (Tam) or Enzalutamide (Enz) on hormone receptor-positive breast and prostate cancer (BC and PC), respectively. The antiproliferative and apoptotic effects of Tam or Enz alone and in combination with UA on MCF7 and LNCaP cancer cells were detected. The results of the WST-1 assay indicated that UA was a promising anticancer compound that significantly enhanced the effectiveness of hormone therapy drugs compared with each drug alone (combination index < 1). In addition, the combination of UA with Tam or Enz remarkably induced more cell cycle arrest at the G0/G1 phase and apoptosis than only drug-treated cells (P < 0.01). Consequently, our findings suggest that the combination of UA with Tam or Enz may be a potential therapeutic approach for the treatment of BC and PC and further studies are required to exploit the potential mechanisms of synergistic effects.
本研究旨在探讨乌头酸（UA）与他莫昔芬（Tam）或恩杂鲁胺（Enz）联合应用对激素受体阳性乳腺癌和前列腺癌（BC 和 PC）的影响。检测了 Tam 或 Enz 单独及与 UA 联合应用对 MCF7 和 LNCaP 癌细胞的增殖和凋亡作用。WST-1 检测结果表明，UA 是一种很有前途的抗癌化合物，与单独使用每种药物相比，显著增强了激素治疗药物的疗效（组合指数<1）。此外，UA 与 Tam 或 Enz 的联合应用比单独用药诱导更多的细胞周期停滞在 G0/G1 期和细胞凋亡（P<0.01）。因此，我们的研究结果表明，UA 与 Tam 或 Enz 的联合应用可能是治疗 BC 和 PC 的一种潜在的治疗方法，需要进一步研究以探索协同作用的潜在机制。
